BUDGET IMPACT OF ORAL NIRMATRELVIR/RITONAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN THE US

被引：0
|
作者：
Sandin, R. [1 ]
Veenstra, D. [2 ]
Dzingina, M. [3 ]
Vankelegom, M. [4 ]
Sullivan, S. [2 ]
Campbell, D. [5 ]
Ma, C. [4 ]
Harrison, C. [4 ]
Draica, F. [6 ]
Wiemken, T. L. [6 ]
Mugwagwa, T. [6 ]
机构：
[1] Pfizer AB, Stockholm, Sweden
[2] Curta Inc, Seattle, WA USA
[3] Pfizer, London, England
[4] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[5] Curta Inc, S Kingstown, RI USA
[6] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE644
引用
收藏
页码：S177 / S177
页数：1
相关论文
共 50 条
  • [11] Comparison of the effectiveness of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in the treatment of COVID-19 moderate hospitalized patients with severe high-risk factors
    Zhang, Yu Ting
    Gu, Jia Ping
    Chen, Jia Yun
    Wang, Huan
    Zhou, Ji Yun
    Zhang, Xiao Qiang
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [12] Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study
    Chen, Xiaohua
    Zhu, Ying
    Shen, Leer
    Zhou, Dan
    Feng, Nannan
    Tong, Qiang
    JOURNAL OF INTENSIVE CARE MEDICINE, 2024, 39 (08) : 742 - 750
  • [13] Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
    Butt, Adeel Ajwad
    Yan, Peng
    Shaikh, Obaid S.
    PLOS ONE, 2024, 19 (06):
  • [14] Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
    Hung, Yuan-Pin
    Lee, Jen-Chieh
    Chiu, Chun-Wei
    Lee, Ching-Chi
    Tsai, Pei-Jane
    Hsu, I-Lin
    Ko, Wen-Chien
    ANTIBIOTICS-BASEL, 2022, 11 (02):
  • [15] Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19
    Hammond, Jennifer
    Yunis, Carla
    Fountaine, Robert J.
    Luscan, Gerald
    Burr, Aimee M.
    Zhang, Wuyan
    Wisemandle, Wayne
    Soares, Holly
    Baniecki, Mary Lynn
    Hendrick, Victoria M.
    Kalfov, Veselin
    Pypstra, Rienk
    Rusnak, James M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 224 - 234
  • [16] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
  • [17] Clinical effectiveness and safety of simnotrelvir/ritonavir and nirmatrelvir/ritonavir in the treatment of moderate to severe COVID-19 patients
    Shi, Ji Chan
    Chen, Xin
    Lin, Xiao Qing
    Cheng, Fang
    Zheng, Shi Lin
    Zhang, Qiang
    Wu, Te
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [18] Nirmatrelvir-ritonavir for COVID-19
    McDonald, Emily G.
    Lee, Todd C.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (06) : E218 - E218
  • [19] US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients
    Cullen, Mark R.
    Zhou, Xiaofeng
    Kelly, Scott P.
    Liang, Caihua
    Li, Ling
    Shen, Rongjun
    Leister-Tebbe, Heidi K.
    Terra, Steven G.
    Gaffney, Michael
    Russo, Leo
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2024, 101
  • [20] Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19)
    Ganatra, Sarju
    Dani, Sourbha S.
    Ahmad, Javaria
    Kumar, Ashish
    Shah, Jui
    Abraham, George M.
    McQuillen, Daniel P.
    Wachter, Robert M.
    Sax, Paul E.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 563 - 572
12345